Patient is currently receiving or has received systemic corticosteroids within <  weeks prior to treatment start, or who have not fully recovered from side effects of such treatment\r\n* The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
Currently receiving or has received systemic corticosteroids (=<  days prior to registration, or who have not fully recovered from side effects of such treatment); NOTE: The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
Participants who are currently receiving or have received systemic corticosteroids =<  weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment; the following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
The following uses of corticosteroids are permitted: single doses, topical applications (e.g.: for rash), inhaled sprays (e.g.: for obstructive airways diseases), eye drops or local injections (e.g.: intra-articular)
Patient is currently receiving or has received systemic corticosteroids =<  weeks prior to starting study drug at a dose greater than the equivalent of  mg prednisone/day, or who have not fully recovered from the side effects of such treatment; the following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
Patients with long-term glucocorticosteroid use; the following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
Participant is currently receiving or has received systemic corticosteroids ? weeks prior to starting study drug, or has not fully recovered from side effects of such treatment. Note: The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops, or local injections (e.g., intra-articular).
Patient is currently receiving or has received systemic corticosteroids =<  weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment\r\n* The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
Patient is currently receiving or has received systemic corticosteroids =<  weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment\r\n* The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
Systemic corticosteroids except as part of on label treatment prostate cancer regimens. Note: Topical applications (eg, rash), inhaled sprays (eg, obstructive airways diseases), eye drops or local injections (eg, intra-articular) are allowed.
History of venous thromboembolism within prior  months; chronic, systemic corticosteroid use for palliative or supportive purpose is not permitted; use of corticosteroids as symptomatic treatment may be allowed on individual basis and upon discussion with the sponsor; acute emergency administration, topical applications, inhaled sprays, eye drops or local injections of corticosteroids are allowed
Subject is currently receiving or has received systemic corticosteroids < days prior to starting study drugs. The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular).
Patient is currently receiving or has received systemic corticosteroids =<  weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment\r\n* The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
Patient is currently receiving or has received systemic corticosteroids =<  weeks prior to starting study drug, or has not fully recovered from side effects of such treatment; the following uses of corticosteroids are permitted: single doses, topical application (e.g., for rash), inhaled sprays (e.g., for obstructive airway diseases), eye drops or local injections (e.g., intra-articular)
Patient is currently receiving increasing or chronic treatment (>  days) with corticosteroids or another immunosuppressive agent, as chronic administration of corticosteroids (>  days) can induce cytochrome P, family , subfamily A, polypeptide  (CYPA); see also section concomitant medication; the following uses of corticosteroids are permitted: single doses; e.g. with standard premedication for infusions; topical applications (e.g., rash), inhaled sprays (e.g., obstructive airways diseases), eye drops or local injections (e.g., intra-articular); patients may take mg or less (or equivalent) of oral prednisone daily
The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
Patient is currently receiving or has received systemic corticosteroids (=<  weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment)\r\n* The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
Patient is currently receiving or has received systemic corticosteroids within =<  weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment; NOTE: the following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
Patient is currently receiving increasing or chronic treatment (>  days) with corticosteroids or another immunosuppressive agent; the following uses of corticosteroids are permitted: single dose, topical applications (e.g., rash), inhaled sprays (e.g., obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
Patient is currently receiving increasing or chronic treatment (>  days) with corticosteroids or another immunosuppressive agent; the following uses of corticosteroids are permitted: single doses; e.g. with standard premedication for taxanes; topical applications (e.g., rash), inhaled sprays (e.g., obstructive airways diseases), eye drops or local injections (e.g., intra-articular); patients requiring chronic therapy with steroids may take no more than  mg daily of prednisone or equivalent
topical applications for treatment of e.g., rash, inhaled sprays for treatment of e.g., obstructive airways diseases, eye drops or local Protocol No. PQR- Protocol Amendment ,  September  PIQUR Therapeutics AG - Confidential Page  of  injections (e.g., intra-articular);
Patient is currently receiving increasing or chronic treatment (>  days) with corticosteroids or another immunosuppressive agent, as chronic administration of corticosteroids (>  days) can induce cytochrome P, family , subfamily A, polypeptide  (CYPA)\r\n* The following uses of corticosteroids are permitted: single doses; e.g. with standard premedication for taxanes; topical applications (e.g., rash), inhaled sprays (e.g., obstructive airways diseases), eye drops or local injections (e.g., intra-articular)
Prolonged systemic corticosteroid treatment, except for topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airway diseases), eye drops, or local insertion (e.g., intra-articular)\r\n* Note: Short duration (<  weeks) of systemic corticosteroids is allowed (e.g., for chronic obstructive pulmonary disease), but not within  days prior to registration
